To evaluate the efficacy of osimertinib in treating HER2-positive ductal carcinoma in situ (DCIS) in a patient with concurrent non-small cell lung cancer (NSCLC), emphasizing the relevance of NSCLC treatment to the study.
Key Findings:
The patient showed a significant reduction in DCIS tumor size from 28 × 11 × 29 mm to 8 × 3 mm after osimertinib treatment, indicating a positive therapeutic response.
Ki-67 index decreased from 20-30% to 1%, suggesting a marked reduction in cell proliferation, which is critical for assessing treatment efficacy.
In vitro studies demonstrated that osimertinib inhibited cell proliferation in a HER2 expression-dependent manner, supporting the clinical findings.
Interpretation:
The findings suggest that osimertinib may have a therapeutic effect on HER2-positive DCIS, potentially due to its inhibitory action on HER2, as evidenced by both clinical and in vitro results.
Limitations:
This is a single case report, limiting generalizability and necessitating caution in interpreting results.
Further clinical trials are needed to establish the efficacy of osimertinib in HER2-positive breast cancer, particularly focusing on larger sample sizes and diverse populations.
Conclusion:
Osimertinib shows promise as a potential treatment for HER2-positive DCIS, warranting further research to explore its role in breast cancer therapy, particularly in clinical trials.
